# RPID earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/RPID) · [Earnings tab](https://www.lopjlb.com/stock/RPID?tab=earnings)

Updated: 2026-08-08T05:48:52

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly call summaries from Q3 2024 through Q2 2026, RPID has shown a steady acceleration of top‑line revenue, moving from $7.6 M (+24% YoY) to $8.1 M (+11% YoY) while expanding system placements from a record 7 in 2024 Q3 to 190 total systems by 2025 Q4 and 196 by 2026 Q1. Gross margin has evolved from an early inflection near +8 % to a record 15 % in 2026 Q2, with management now targeting >50 % by 2028. The MilliporeSigma global distribution agreement introduced in 2024 Q4 remains a central partnership, described as on‑track and accelerating in later quarters. Capital strategy shifted with a $45 M term loan in 2025 Q2 and a stable cash position (~$20‑23 M) supported by a $25 M credit facility. Validation activity, initially noted as on‑track in 2025 Q2, was expanded to a 27+ target in 2026 Q2. Early macro‑economic and pharma‑spending concerns cited in 2025 Q2 disappear from subsequent updates, suggesting reduced relevance. Overall, the narrative reflects improving financial metrics, advancing partnerships, and a focus on margin expansion and validation capacity.

## Latest CallCard · Q2

RPID Q2 revenue $8.1M (+11% YoY), 4 placements, 9 validations, record 15% gross margin; reaffirms FY26 guidance, raises validation target to 27+; MilliporeSigma partnership accelerating; targets 50%+ gross margin by 2028. Cash ~$20M, efficiency program saves $1M H2.

**Guidance:** vague

**Tone:** mgmt 0.4 · Q&A pressure 0.35 · divergence 0.05

Management highlights record consumables, margin inflection, validation pipeline, MilliporeSigma progress, reshoring tailwinds, and states fundamentals stronger than any point in history while reaffirming guidance and raising validation target.

## Quarter one-liners

- **2026 Q2:** RPID Q2 revenue $8.1M (+11% YoY), 4 placements, 9 validations, record 15% gross margin; reaffirms FY26 guidance, raises validation target to 27+; MilliporeSigma partnership accelerating; targets 50%+ gross margin by 2028. Cash ~$20M, efficiency program saves $1M H2.
- **2026 Q1:** RPID Q1 revenue $8M (+11% YoY), 6 system placements (196 total); reaffirmed FY26 revenue $37-41M, 30-38 placements; gross margin 5% in Q1, targeting ~20% FY26 with Q4 mid-20% exit; MilliporeSigma partnership expanding services and supply agreement; cash $23M plus $25M credit facility.','tone': {'mgm
- **2025 Q4:** RPID Q4 revenue $11.3M (+37% YoY), 16 system placements, 190 total systems; FY2026 guidance $37-41M revenue, 30-38 placements, ~20% gross margin; Samsung Biologics expansion order, Amgen multisystem rollout, MilliporeSigma partnership progress, next-gen cloud-native software H2 2026. Q4 inventory wr
- **2025 Q3:** RPID beats Q3 guidance with $7.8M revenue, raises FY25 guide to $33M+ on record multi-system order; consumables +40%, gross margin 9%; MilliporeSigma supply deal to boost
- **2025 Q2:** Revenue rose 10% to $7.3M with positive gross margins, a new $45M term loan and reaffirmed full‑year guidance, but pharma timing and trade dynamics keep system placements near the low end of outlook.
- **2025 Q1:** —
- **2024 Q4:** RPID Q4 revenue $8.2M (+30% YoY), 6 system placements; announced MilliporeSigma global distribution deal with minimum purchase commitments weighted to 2026; 2025 guidance $32M+ revenue, 21-25 placements, no MilliporeSigma contribution assumed. Gross margin inflection to 12% in Q4, breakeven full yea
- **2024 Q3:** RPID Q3 revenue $7.6M (+24% YoY), record 7 system placements, gross margin inflection to +8%, reaffirms FY24 revenue ≥$27M, targets positive cash flow by

## Theme arcs

- **Revenue growth** (improving): Revenue rose from $7.6M in 2024 Q3 to $8.1M in 2026 Q2, with FY guidance climbing to $41M.
- **System placements / installed base** (improving): Placements grew from 7 in 2024 Q3 to 190 total systems by 2025 Q4 and 196 by 2026 Q1.
- **Gross margin trajectory** (improving): Margin moved from +8% inflection to 15% record in 2026 Q2, with a target >50% by 2028.
- **MilliporeSigma partnership** (improving): Launched in 2024 Q4, later described as on‑track and accelerating.
- **Capital liquidity** (stable): Introduced $45M term loan in 2025 Q2; cash remains ~ $20‑23M with a $25M credit facility.
- **Validation activity** (improving): Validation count on‑track in 2025 Q2, target raised to 27+ in 2026 Q2.
- **Macro‑economic/trade risk** (resolved): Cited as a fear in 2025 Q2 but not mentioned in later calls.
- **Pharma spending risk** (resolved): Raised in 2025 Q2, absent from subsequent updates.
- **Site readiness risk** (resolved): Construction delays noted in 2025 Q2, no later references.
- **Margin pressure risk** (resolved): Tariff‑driven margin pressure flagged in 2025 Q2, not repeated later.

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/RPID`